Plain-English translation of NCT07263906 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called LILRA6 CAR-T cell therapy for patients with acute myeloid leukemia (AML) that has come back or stopped responding to chemotherapy. The treatment works by taking your own immune cells, engineering them in the lab to recognize and fight your cancer cells, and then putting them back into your body. This trial will first test different doses of the medication in a small group of patients to make sure it is safe, then expand to a larger group to see how well it works.
Acute myeloid leukemia that returns or doesn't respond to standard chemotherapy is very difficult to treat, and patients with this type of cancer need new options. This medication is designed to harness your own immune system to target and destroy leukemia cells in a way that traditional chemotherapy cannot.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy to prepare your body for the new treatment. Then, your immune cells will be collected and sent to the lab to be engineered. Once the new cells are ready, you will receive them back through an intravenous infusion (through a vein). You will be closely monitored for at least 28 days after the infusion to watch for side effects, and then you will continue to be followed for up to 2 years to see how well the treatment is working and to check your long-term health.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Enrollment target
~48 participants
Started
December 2025
Primary completion
October 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenbin Qian, Professor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.